On March 31, 2025, Isomorphic Labs, an AI-first drug design and development company, announced it has raised $600 million in its first external funding round led by Thrive Capital, with participation from GV, and follow-on capital from existing investor Alphabet. Wilson Sonsini Goodrich & Rosati advised Isomorphic Labs on the transaction.

Isomorphic Labs was founded with the ambition to reimagine the entire drug discovery process from first principles with an AI-first approach, to bring much-needed treatments to millions of patients globally. The company aims to apply its pioneering unified AI drug design engine to deliver biomedical breakthroughs and is advancing drug design programs across multiple therapeutic areas and drug modalities. The funding will fuel advancements in frontier AI research and development, to rapidly advance the company’s next-generation AI drug design engine, and scale and progress drug candidate pipelines.

The Wilson Sonsini team that advised Isomorphic Labs on the transaction includes Allison Spinner, Adam Bloom, Andrew Gillman, and Betty Rosenbaum.

For more information, please see Isomorphic Labs' news release. Additional coverage can be found on TechCrunch and Reuters.